Education
About Us
Working with TipRanks
Follow Us
CervoMed (CRVO)
NASDAQ:CRVO
CRVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.80 - $25.92
Previous CloseN/A
Volume72.82K
Average Volume (3M)9.28M
Market Cap
$86.85M
Enterprise Value$80.40M
Total Cash (Recent Filing)$465.47K
Total Debt (Recent Filing)$2.17M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Apr 07, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding8,702,719
10 Day Avg. Volume2,517,967
30 Day Avg. Volume9,280,599
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.77
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.41
Forecast
1Y Price Target
$15.83Price Target Upside40.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Investor ConfidenceCervoMed's latest data from the open label extension (OLE) study is boosting investor confidence, and a more risk-on approach is seen heading into the next steps for neflamapimod in dementia with Lewy bodies (DLB) patients.
Product EfficacyNewly manufactured capsules of neflamapimod have meaningfully improved CDR-SB scores compared to old capsules in the initial 16 weeks, indicating significant cognitive benefits.
Bears Say
Clinical Trial ResultsThe trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (CDR-SB) or any of its key secondary endpoints.
Market UncertaintyDisappointing neflamapimod clinical data creates uncertainty—downgrading to Neutral without a price target.
---
Ownership Overview
48.27% Insiders
6.92% Mutual Funds
1.97% Other Institutional Investors
36.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $1.80 and its highest was $25.92 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $86.85M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Apr 07, 2025 which is in 3 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Nov 12, 2024. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.138.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.64.
How many shares outstanding does CervoMed have?
CervoMed has 8,702,719 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went down -2.554%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
---
CervoMed Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.83 (40.84% Upside)
$15.83 (40.84% Upside)
Hedge Fund Trend
Decreased
By 742.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 19.6%
Last 30 Days ▲ 19.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.71%
12-Months-Change
Fundamentals
Return on Equity
-69.95%
Trailing 12-Months
Asset Growth
335.75%
Trailing 12-Months
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
---
CRVO Stock 12 Month Forecast
Average Price Target
$15.83
▲(40.84% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Biogen
―
Cassava Sciences
―
Anavex Life Sciences
―
Axsome Therapeutics
―
Best Analysts Covering CRVO
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
+91.84%
reiterated a buy rating 19 days ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +91.84% per trade.
---